Noxopharm Ltd. has released a press release.
New preclinical data supports immuno-oncology approach
Earlier from Noxopharm
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference